Inspire Pharmaceuticals (ISPH) to Initiate Phase 2 Trials of Epinastine for Seasonal Allergic Rhinitis
More News related to ISPH
- Inspire Announces Webcast of Presentation at Piper Jaffray Health Care Conference
- Inspire Pharma (ISPH) posts Q3 Loss of $0.12, Bests By 3c
- Inspire Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
More News related to FDA
- Somaxon (SOMX) Volatile Into FDA Action Date
- Vivus (VVUS) Higher Ahead of Qnexa NDA
- Cardium (CXM) Subsidiary Files 510(k) with U.S. FDA for Excellagen Marketing Clearance
- Cardium (CXM) Files FDA 510(k) Application for Marketing Clearance of ExcellagenXL(TM) Topical Gel and Flowable Collagen
- Spectranetics (SPNC) Receives U.S. FDA OK for VisiSheath Dilator Sheath Device
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the treatment of seasonal allergic rhinitis.
This Phase 2 clinical trial is a 14-day randomized, double-blind comparison of two doses of epinastine nasal spray (0.05% and 0.1%) to placebo in approximately 580 subjects who have a documented history of seasonal allergic rhinitis to mountain cedar pollen.
Inspire previously acquired certain exclusive rights from Boehringer Ingelheim to develop and market an intranasal dosage form of epinastine in the United States and Canada for the treatment or prevention of rhinitis.
Related Categories
FDAStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
